NASDAQ Healthcare Biotechnology CTIC

CTI BioPharma Corp.

$ 9.10 0.06 %

CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.

CEO: Adam R. Craig - https://www.ctibiopharma.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$10.4 14.35 %

Recommandation

Buy

DCF

$ -

Loading data...

CTIC vs S&P500

Loading data...

No data available.

Quick ratio

1.22

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-16.84

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.54

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

1 318.48 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

-84.24 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

-

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

-2.84

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-0.93

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
-27.06 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.37 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.40 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.